
Quarterly report 2025-Q3
added 11-05-2025
Penumbra Net Debt 2011-2026 | PEN
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Penumbra
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -290 M | -133 M | -35 M | -24.6 M | -20.8 M | 9.52 M | -67.8 M | -50.6 M | -13.2 M | -19.5 M | -3.29 M | 1.87 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.52 M | -290 M | -53.9 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AxoGen
AXGN
|
21.9 M | $ 33.22 | 1.87 % | $ 1.47 B | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
Aziyo Biologics
AZYO
|
1.36 M | - | 1.37 % | $ 20.5 M | ||
|
Cognyte Software Ltd.
CGNT
|
-47.4 M | $ 7.01 | 2.04 % | $ 503 M | ||
|
Apyx Medical Corporation
APYX
|
-10.1 M | $ 3.76 | -1.7 % | $ 130 M | ||
|
Alphatec Holdings
ATEC
|
442 M | $ 13.29 | 1.41 % | $ 1.9 B | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
Bio-Rad Laboratories
BIO
|
754 M | $ 255.19 | -12.51 % | $ 7.2 B | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
1.91 B | $ 36.35 | -3.09 % | $ 5.42 K | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
CONMED Corporation
CNMD
|
889 M | $ 41.59 | -0.28 % | $ 1.28 B | ||
|
Boston Scientific Corporation
BSX
|
8.64 B | $ 74.77 | 0.88 % | $ 110 B | ||
|
Abbott Laboratories
ABT
|
5.26 B | $ 112.22 | 0.66 % | $ 195 B | ||
|
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | ||
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 4.8 | 0.63 % | $ 179 M | ||
|
Delcath Systems
DCTH
|
-2.46 M | $ 9.25 | 1.43 % | $ 264 M | ||
|
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
ClearPoint Neuro
CLPT
|
-16.5 M | $ 13.44 | 3.07 % | $ 363 M | ||
|
Electromed
ELMD
|
-10.5 M | $ 24.2 | 3.82 % | $ 205 M | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
Inogen
INGN
|
-94.4 M | $ 5.71 | -1.38 % | $ 135 M | ||
|
InMode Ltd.
INMD
|
-34.8 M | $ 14.36 | 0.38 % | $ 1.14 B | ||
|
IRadimed Corporation
IRMD
|
-52.1 M | $ 99.81 | -0.03 % | $ 1.26 B | ||
|
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | ||
|
Integer Holdings Corporation
ITGR
|
941 M | $ 85.46 | 0.23 % | $ 2.87 B | ||
|
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
FONAR Corporation
FONR
|
-42.8 M | $ 18.55 | 0.05 % | $ 122 M | ||
|
Pulmonx Corporation
LUNG
|
-36.1 M | $ 1.47 | 3.17 % | $ 57.5 M | ||
|
Globus Medical
GMED
|
-774 M | $ 87.89 | 0.76 % | $ 11.9 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 11.29 | 4.46 % | $ 869 M | ||
|
Myomo
MYO
|
-4.79 M | $ 0.82 | 0.41 % | $ 5.78 M | ||
|
Establishment Labs Holdings
ESTA
|
131 M | $ 75.22 | 2.28 % | $ 2.12 B |